IN8bio to Present at Upcoming Investor and Scientific Conferences in February
IN8bio, Inc. (INAB)
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (?d ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Investor Registration IO360° ConferenceDate: Thursday, February 12, 2026Time: 1:20 p.m. – 1:40 p.m. ETSession: IO Clinical Advancements Plenary Presentation title: IN8bio’s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM Additional details, including any available webcast information, will be posted on the Events & Presentations section of the Company’s website at www.in8bio.com. About IN8bio IN8bio
Show less
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]Yahoo! Finance
- IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed GlioblastomaGlobeNewswire
- IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]Yahoo! Finance
INAB
Earnings
- 5/7/25 - Miss
INAB
Sec Filings
- 1/30/26 - Form 424B3
- 1/29/26 - Form SCHEDULE
- 1/29/26 - Form EFFECT
- INAB's page on the SEC website